Authored By: Sarah
09 Aug 2024

 Regenerative Medicine Market Size to grow by USD 70.11 billion between 2024-2028

According to a research report “ Regenerative Medicine Market” by Application (Oncology, Musculoskeletal, Dermatology, Immunology and inflammation and others) Technology (Cell, tissue-based, Gene therapy) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 70.11 billion, at a CAGR of 23.31% during the forecast period. In the global business landscape, chronic diseases such as heart disease, diabetes, stroke, cancer, obesity, and arthritis pose a substantial challenge, affecting a significant portion of the population and imposing a heavy economic burden on healthcare systems. In the US alone, a large demographic battles one or more chronic health conditions, with one in four adults dealing with two or more. Unhealthy lifestyle choices, including sedentary habits, poor nutrition, and substance abuse, are primary contributors to the development of these conditions. Simultaneously, the prevalence of acute and chronic wounds, including surgical and traumatic injuries (abrasion, puncture, laceration, and incision) and chronic conditions like venous ulcers, diabetic ulcers, and pressure ulcers, continues to rise. These wounds not only impact the quality of life of affected individuals but also place a significant strain on healthcare resources. Regenerative medicine, with its potential to restore and replace damaged cells, tissues, and organs, offers a promising solution to mitigate the burden of these conditions..

Browse market data tables, figures, and in-depth TOC on “Regenerative Medicine Market” by Application (Oncology, Musculoskeletal, Dermatology, Immunology and inflammation and others) Technology (Cell, tissue-based, Gene therapy) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

By Application, the Oncology segment is projected to dominate the market size in 2024

The global regenerative medicines market is experiencing robust growth, particularly in the oncology application segment. This trend is driven by several factors, including the rising incidence of cancer as reported by organizations such as the World Health Organization (WHO) and the European Medicines Agency (EMA). For instance, the WHO estimates that there will be approximately 14.6 million new cancer cases worldwide in 2022, with India projected to have the highest number of cases at 1,004,575 (100.4 per 100,000), and 7,492,511 (105.1) of these cases being female. This increasing cancer burden underscores the significant market potential for regenerative medicines in the oncology sector.

By Technology, Cell  segment is expected to hold the largest market size for the year 2024

In the realm of regenerative medicine, cell therapy and tissue engineering are two transformative technologies that hold immense potential for restoring the functionality of diseased or damaged organs. Cell therapy involves the administration of living cells, derived from somatic sources such as embryonic stem cells, progenitor cells, hematopoietic stem cells, and mesenchymal stem cells, into an individual's body to initiate healing processes. Conversely, tissue engineering is an interdisciplinary approach that merges life sciences and engineering principles to develop products containing a combination of cells and biologically active molecules. These tissue-engineered products can be derived from human or animal sources, and may consist of viable or non-viable cells or tissues, with the ultimate goal of improving or replacing damaged biological tissues.

North America is forecasted to hold the largest market size by region in 2024

In North America, the regenerative medicine market is experiencing significant growth, driven by the presence of approximately 510 companies engaged in the production and development of regenerative medicines. Key vendors, including Integra LifeSciences, MiMedx, Organogenesis, and Zimmer Biomet Holdings Inc., are contributing to this expansion through the launch of innovative products and strategic sales force reorganization. Factors such as the increasing prevalence of chronic and acute diseases, a rapidly aging population, high end-user awareness, and the high adoption of cell and tissue-based therapies and gene therapies are fueling market growth. Additionally, the region's significant presence of tissue banks and a strong focus on regenerative medicine further bolster market prospects.

The Regenerative Medicine Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Becton Dickinson and Co.
  • Cook Group Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • Integra Lifesciences Corp.
  • Johnson and Johnson
  • Medtronic Plc
  • Merck and Co. Inc.
  • Mesoblast Ltd.
  • MiMedx Group Inc.
  • Novartis AG
  • Nuvasive Inc.
  • Organogenesis Holdings Inc.
  • Smith and Nephew plc
  • Thermo Fisher Scientific Inc.
  • Vericel Corp.
  • Zimmer Biomet Holdings Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The regenerative medicine market is experiencing significant growth due to advancements in various therapeutic areas, including oncology, wound care, and orthopedics. Innovative pipeline candidates, such as platelet rich plasma, tissue engineering, cell therapy, and CAR-T treatment, are revolutionizing healthcare. Companies like CellPoint and Integra LifeSciences are leading the charge with their R&D capabilities and research grants. In oncology, regenerative medicine is being used to develop new therapies for cancer treatment. For instance, CAR-T treatment, which uses genetically modified T-cells to target and destroy cancer cells, is showing promising results. In wound care, tissue engineering and cellular therapies are being used to regenerate damaged tissues, reducing healing time and improving patient outcomes. Orthopedics is another area where regenerative medicine is making a significant impact. Platelet rich plasma and cell therapy are being used to repair skeletal muscles and vasculature, leading to improved mobility and reduced pain. Moreover, regenerative medicine is also being explored for the treatment of chronic genetic disorders, such as CRISPR therapy and gene therapy, which hold the potential to cure rare diseases and blood cancers through personalized medicine. The global healthcare expenditure on regenerative medicine is expected to grow exponentially in the coming years, making it an exciting and dynamic field to watch. The TRIM72 protein, a potential target for regenerative medicine, is also gaining attention for its role in cellular repair and maintenance.

Market Research Overview

Regenerative medicines, including cell-based therapies, are revolutionizing healthcare by offering innovative solutions for various medical conditions. The market for regenerative medicines is expanding rapidly, with significant growth in the Cardiovascular and Oncology segments. The prevalence of cancer-related deaths and the high prevalence of diabetes and age-related disorders drive the demand for therapeutics in these segments. Tissue-based regenerative therapies, such as those using stem cells, are at the forefront of this trend. In the Oncology segment, companies like BlueRock Therapeutics are developing regenerative therapies for bones, muscles, ligaments, tendons, and cartilage using stem cells. In the Therapeutics segment, gene editing technology and genomic research in cell biology are driving innovation. Clinical trials for regenerative therapies are underway for vision disorders like those affecting Bruch's membrane and the choriocapillaris, spinal cord injuries, neurodegenerative diseases like Alzheimer's, and even rare diseases. Regenerative medicine encompasses a wide range of therapeutic categories, including gene-based therapies and molecular medicines using platforms like CAR-T and T-ChargeTM. Traditional surgeries and orthopedic challenges are being challenged by these innovative pipeline candidates. Nanotechnology and dermatology are also areas of interest in regenerative medicine. Funding initiatives, adaptive regulatory approaches, and orphan drug designations are driving the growth of this industry. The European Medicines Agency (EMA) and the FDA are supporting the development of regenerative therapies through the RMAT designation. The conventional treatment approach is being replaced by biological therapies, and academic research institutes, clinics, hospitals, and government organizations are investing heavily in this field. The future of regenerative medicine lies in personalized medicine and the treatment of chronic genetic disorders using CRISPR therapy and gene therapy. The potential applications of regenerative medicine are vast, from diabetes type 1 & 2 to cancer, and the healthcare expenditure on these conditions is expected to increase significantly in the coming years. The future of regenerative medicine holds great promise for patients and the healthcare industry as a whole.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!

Safe and Secure SSL Encrypted

Technavio

  • 2500 USD

[5 reports/month/user]

  • 5000 USD

close
  • Basic Plan [5000 USD/Year]:

    Single User
    Download 5 Reports/Month
    View 100 Reports/Month
    Add upto 3 Users at 625 USD/user

  • Teams Plan [7500 USD/Year]:

    5 User
    Download 5 Reports/Month/User
    View 100 Reports/Month/User
    Add upto 30 Users at 500 USD/user

*You can upgrade to Teams plan at Subscription page

close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization).
    Complimentary Customization Included

*For Enterprise license, go to checkout page

Technavio Get the report (PDF) sent to your email within minutes.